Replies to post #236511 on Biotech Values

[DewDiligence]

re: MYOV’s Orgovyx (relugolix) for prostate cancer, do you have an opinion if that drug significantly increases survival rate for prostate cancer…?

The phase-3 trial resulting in Orgovyx’s FDA approval (https://www.clinicaltrials.gov/ct2/show/NCT03085095 ) did not measure overall survival, and PFS is just a secondary endpoint that hasn’t yet been analyzed, so the short answer to your question is: probably not.

However, Orgovyx does seem to be the best drug in the androgen-deprivation class based on sustained testosterone suppression (the primary endpoint of the above study) without an initial spike, superior cardiovascular safety compared to other agents in the class, and the convenience of oral administration.